COGT - Cogent Biosciences, Inc.
About Cogent Biosciences, Inc. (https://www.cogentbio.com)
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Andrew R. Robbins | President, Chief Executive Officer & Director | 1976 | $1,321,754 USD |
| Jessica Sachs | Chief Medical Officer | 1975 | $896,623 USD |
| John Edward Robinson | Chief Scientific Officer | 1974 | $868,743 USD |
| John L. Green | Chief Financial Officer & Principal Accounting Officer | 1980 | $834,275 USD |
| Cole Pinnow | Chief Commercial Officer | 1975 | $754,602 USD |
| Abb Hayden | Senior Vice President of Sales | – | – |
| Brad Barnett | Chief Technology Officer | – | – |
| Christi Waarich | Senior Director of Investor Relations | – | – |
| Dana R. Martin | Senior Vice President of Medical Affairs & Chief Patient Officer | – | – |
| Erin Schellhammer | Chief People Officer | – | – |
| Evan D. Kearns | Chief Legal Officer & Corporate Secretary | 1980 | – |